Drug profile · INN
ganciclovir sodium
GANCICLOVIR SODIUM
ganciclovir sodium (GANCICLOVIR SODIUM) is a human herpesvirus 1 dna polymerase inhibitor. Associated with Regeneron Ireland Designated Activity Company (DAC). Route of administration: injection. Current US regulatory status: approved.
Drug details — ganciclovir sodium
- US status
- approved
- Class
- —
- Route
- INJECTION
- Patents
- 0
- Programs
- 0
- Data quality
- 0.89
Quick answer
ganciclovir sodium (GANCICLOVIR SODIUM) is a human herpesvirus 1 dna polymerase inhibitor. Associated with Regeneron Ireland Designated Activity Company (DAC). Route of administration: injection. Current US regulatory status: approved.
Key facts
Mechanism of action
Human herpesvirus 1 DNA polymerase inhibitor
Primary target: DNA polymerase catalytic subunit
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Related & competitor drugs
Frequently asked questions
What is ganciclovir sodium?
ganciclovir sodium (GANCICLOVIR SODIUM) is a human herpesvirus 1 dna polymerase inhibitor. Associated with Regeneron Ireland Designated Activity Company (DAC). Route of administration: injection. Current US regulatory status: approved.
What is the brand name for ganciclovir sodium?
GANCICLOVIR SODIUM is a marketed brand name for ganciclovir sodium. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of ganciclovir sodium?
ganciclovir sodium has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.